Biotech Arena Stock Rises On Study In Crohn’s Disease | Investor’s Business Daily

Arena stock jumped early Tuesday on promising data for its non-opioid treatment for Crohn’s disease pain. Olorinab acts on the cannabinoid receptor type 2.

Source: Biotech Arena Stock Rises On Study In Crohn’s Disease | Investor’s Business Daily

Your Thoughts?